MarketPulse

cardiometabolic disease

4 articles
BenzingaBenzinga··Nabaparna Bhattacharya

Esperion Soars 57% on $1.1B ARCHIMED Buyout Deal

Esperion Therapeutics agreed to be acquired by ARCHIMED for $1.1 billion, with shareholders receiving $3.16 per share plus up to $100 million in contingent payments—a 58% premium driving 57.5% premarket gains.
ESPRacquisitionshareholder value
BenzingaBenzinga··Na

Esperion Closes Corstasis Acquisition, Adds First Nasal Spray Loop Diuretic to CV Portfolio

Esperion closes Corstasis acquisition, gaining FDA-approved Enbumyst nasal spray loop diuretic for heart failure treatment, leveraging existing cardiovascular commercial infrastructure.
ESPRacquisitionFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Esperion Closes Corstasis Deal, Adding First Nasal Loop Diuretic to Heart Drug Arsenal

Esperion completes acquisition of Corstasis, adding Enbumyst, first FDA-approved nasal spray loop diuretic, to expand its cardiovascular product portfolio.
ESPRacquisitionFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Nodthera

NodThera to Present NLRP3 Drug Program at Major April Investor Conferences

NodThera, a clinical-stage NLRP3 inhibitor biotech, will present at major April 2026 investor conferences including Piper Sandler and Needham.
SNYoral therapyclinical-stage biotech